Purpose: The folate receptor (FR) has emerged as an interesting diagnostic and therapeutic drug target with many potential applications in oncologic and inflammatory disorders. It was therefore the aim of this study to develop a folate-derived Ga-68-based positron emission tomography (PET) imaging tracer that is straightforward to radiolabel and could be broadly used in clinical studies. We validated its target binding affinity and specificity and compared it to [ 99m Tc]EC20, the folate single-photon emission computed tomography (SPECT) imaging tracer that has been most extensively studied clinically so far. Procedures: The new folic acid-derived PET imaging agent is linked via a polyethyleneglycol linker to the chelator 1,4,7-triazacyclononane-1,4,7-trisacetic acid (NOTA). This new compound, NOTAfolate, was labeled with gallium-68. We tested the probe's stability in human plasma and its selectivity in vitro, using the FR-positive KB cell line as well as the FR-negative A549 cell line. Ga-NOTA-folate showed very good tumor uptake and retention (6.6 ± 1.1 %ID/g), relatively low kidney uptake (21.7 ± 1.1 %ID/g), and very low liver uptake (0.38 ± 0.08 %ID/g).
Introduction
The folate receptor (FR) has emerged as a valuable target for treating a range of cancers, and several targeted therapies directed toward folate receptors are in late-stage clinical development [1, 2] . These therapies build on the high affinity of folic acid and its derivatives to folate receptors (K D (folate) = 0.1 nM) [3, 4] , paired with the receptor's overexpression in a wide variety of human epithelial cancers [5] [6] [7] [8] . In parallel to the development of FR-targeted therapeutics, radio and optical tracers have been developed, and folate receptor-targeted imaging has been used successfully in preclinical and clinical research [8] [9] [10] [11] [12] [13] [14] . Similar to what is observed for folic acid, conjugates bearing these agents are bound to the folate receptor, and they are transported into the cell by endocytosis [15] . Preclinical and clinical studies also revealed uptake of folate-targeted imaging agents in areas of inflammatory diseases such as rheumatoid arthritis and could be connected to folate receptor expression on activated macrophages [16, 17] .
Clinical studies of folate-targeting drugs would benefit enormously from a method to quantify FR expression levels in whole-body studies as there is well-known inter-and intra-patient variability in FR expression levels in patients with metastatic cancers [18, 19] . The single-photon emission computed tomography (SPECT) imaging agent [ 99m Tc]EC20 was used in several clinical trials as a companion imaging agent for small molecular folate therapeutics. However, a positron emission tomography (PET) imaging agent would have significant advantages, including a faster image acquisition as well as a more robust quantification of the concentration of FR ligands in tumor and normal organs [20] .
With this in mind, we became interested in designing, testing, and validating a folate-targeted probe that allows imaging and easy quantification of folate receptors. Our goal was to validate a small-molecule folate PET agent that (1) quickly distributes throughout tissue, (2) targets folate receptors with high affinity, (3) efficiently clears from nontargeted sites and compartments, and (4) demonstrates high tumor uptake for sensitive detection of FR expression even in small lesions. We not only report the development and preclinical evaluation of this new agent, [
68 Ga]NOTAfolate, but we also compare its in vitro and in vivo performance to the already clinically used SPECT tracer [ 99m Tc]EC20.
Materials and Methods

Materials
Unless otherwise stated, all chemicals and solvents were used without further purification. Water used for this study was ultrapure (918.2 MΩ cm −1 at 25°C), and acetonitrile (CH 3 CN) as well as ethanol were of HPLC grade purity. Chelexed water was prepared with BT Chelex 100 Resin (Bio-Rad) and phosphate-buffered saline (PBS) was purchased from the media preparation facility at Memorial Sloan Kettering Cancer Center. Ascorbic acid and sodium hydroxide were purchased from Sigma-Aldrich as TraceSELECT (999.9 % purity). All other chemicals were acquired from Sigma-Aldrich unless stated otherwise. Waters Sep-Pak C18 Plus Light cartridges were purchased from Fisher Scientific (Pittsburgh, PA). The precursor for PET imaging, NOTA-folate, as well as the labeling kit for radiolabeling EC20 were provided by Endocyte (West Lafayette, IN). Ga-68 was produced by a Ge-68/Ga-68 generator from ANSTO (Sydney, Australia). Sodium [ 99m Tc]pertechnate was supplied by Nuclear Diagnostic Product (Rockaway, NJ). The human epithelial cancer cell line KB as well as the human lung cancer cell line A549 were purchased from ATCC (Manassas, VA) and grown by serial passage. All HPLC purifications and quality controls (0.5 ml/min, buffer A = 0.1 % TFA in water, buffer B = 0.1 % TFA in acetonitrile) were performed on a Shimadzu UFLC HPLC system equipped with a DGU-20A degasser, SPD-M20A UV detector, LC-20AB pump system, CBM-20A communication BUS module, and a Scan-RAM radio-TLC/HPLC-detector form Lablogic using a reversed phase Phenomenex Luna column (2.5 μm, C-18(2)-HST, 50 × 3.0 mm). Liquid chromatography-mass spectrometry (LC-MS) was recorded with an LCMS-2020 Shimadzu system.
Preparation of [
99m Tc]EC20 The preparation of the SPECT imaging tracer [
99m Tc]EC20 was performed according to Leamon et al. [21] using an EC20 labeling kit, containing a lyophilized mixture of EC20 (0.1 mg, 0.13 μmol, 745.2 g/mol); sodium α-D-glucoheptonate (80.0 mg, 0.32 mmol, 248.2 g/mol); tin(II)chloride dihydrate (80.0 mg, 0.35 mmol); and sufficient sodium hydroxide or hydrochloric acid to adjust the pH to 6.8 (prior to lyophilization). Chelexed water (1.0 ml) was added to the vial of the radiolabeling kit. Thereafter, 224 μl of the EC20 Tc]pertechnate (13.9 ± 1.4 mCi, 514 ± 52 MBq, 0.15 ml), and the reaction solution was placed on a thermomixer and agitated at 600 rpm for 30 min at 80°C. After cooling to room temperature, the product was purified using a Sep-Pak C18 light cartridge as previously described [21] . The solution of [
99m Tc]EC20 (11.4 ± 0.65 mCi, 422 ± 24 MBq (decay-corrected), radiochemical yield (RCY) = 82.0 ± 2.9 %) in ethanol/PBS (1:1, 400 μl) with a specific activity of 0.38 ± 0.02 Ci/μmol (14.0 ± 0.07 GBq/ μmol) was further diluted with PBS (1.6 ml) and used for in vitro as well as in vivo studies~60 min post synthesis. .3 ± 1.6 mCi, 344 ± 59 MBq) was added to the reaction mixture (pH = 5.3), and the solution was placed on a thermomixer and agitated at 600 rpm for 15 min at 40°C. After incubation, the [ 68 Ga]NOTA-folate was purified using pre-conditioned SEP-PAK C18 light cartridges to yield the completed radioligand (8.1 ± 1.8 mCi, 300 ± 67 MBq (decay-corrected), RCY = 87.2 ± 6.9 %) in 995 % radiochemical purity in a solution of ethanol/PBS (1:1, 400 μl) with a specific activity of 0.27 ± 0.06 Ci/μmol (9.97 ± 2.22 GBq/μmol). Then, the radioligand was further diluted with PBS (1.6 ml) and used for in vitro as well as in vivo studies~60-min post synthesis.
Cell Culture The human epithelial cancer cell line KB, a folate receptor-positive cell line, and the human cell line A549, a folate receptor-negative lung cancer cell line, were used for in vitro receptor binding studies at passages 3-11. Cell culture was performed as previously described [22] . KB cells were grown in folate-free RPMI 1640 medium (10 % FBS) from Gibco (ThermoFisher) containing L-glutamine (2.0 mM) and sodium bicarbonate buffer (2.0 g/L) and passaged regularly at 70-80 % confluence every 4-5 days. A549 cells were grown in RPMI 1640 medium (10 % FBS) from the media preparation facility at Memorial Sloan Kettering Cancer Center (New York, NY, USA) containing L-glutamine (2.0 mM) and sodium bicarbonate buffer (2.0 g/ L) and passaged regularly at 70-80 % confluence every 3-4 days.
In Vitro Receptor Uptake Assay Twenty-four hours prior to the in vitro studies, KB cells as well as A549 cells (1.0 × 10 6 cells/well, 990 % viability for both lines) were seeded into 6-well plates containing folate-free RPMI 1640 medium (2.0 ml) and incubated to form subconfluent monolayers of the cells. Then, medium was removed from the wells, cells were washed with PBS (1 ml) and medium (900 μl) was added. After 30 min of incubation at 37°C, the radiotracer (0.1 nmol, 100 μl) in PBS was added to the dedicated well (c = 100 nM). For blocking studies, cells were pre-incubated with an excess of folate (c = 10 μM) 5 min prior to the addition of radiotracer. After 30 min post incubation at 37°C, the supernatant of each well was collected together with washing solution (ice-cold PBS, 2 × 1.0 ml). Then, cells were treated with 1 M sodium hydroxide solution (1.0 ml) for 10 min at room temperature. Finally, cell suspension was collected together with washing solution (ice-cold PBS, 2 × 1.0 ml). The radioactivity of all contents including initially added radiotracer (0.1 nmol, 100 μl) was measured using a WIZARD 2 automatic γ-counter from PerkinElmer. Receptor-specific uptake was calculated by cell-bound activity and expressed as a percentage of applied activity per million cells.
Serum Protein Binding
The radiotracers (1.8 ± 0.5 mCi, 67 ± 19 MBq, 360 μl) were incubated while agitated (600 rpm) at 37°C in human serum (1.0 ml, Sigma-Aldrich). At pre-determined time points (30, 60, 120 , and 240 min), 250 μl of the serum was transferred in to a 1.7-ml Eppendorf tube containing ice-cold acetonitrile (250 μl). The resulting mixture was vortexed (1 min) and centrifuged (13,000 rpm) for 5 min. The supernatant was transferred into a 1.7-ml Eppendorf tube followed by additional centrifugation at , viability: 993 %) in a 1:1 mixture of media/matrigel (150 μl) were subcutaneously inoculated into the right shoulder of anesthetized mice (2 % isoflurane gas in 2 l/min medical air) to establish tumors (100-150 mm 3 ) after 7-9 days. For intravenous injections, mice were gently heated with a heating lamp placed on an injection restrainer, tail cleaned with sterilized alcohol pads, and the imaging agent was injected into the lateral tail vain. On average, there was about 60-min delay between the end of the synthesis and administration to the animals.
PET/CT Imaging PET scans were performed using a small-animal Inveon® PET/CT system from Siemens (Knoxville, TN and EC20 (12.5 nmol) was injected into KB tumor-bearing female athymic nude mice (n = 3) vial tail vain. At 1, 2, and 4 h after injection, the mice were anesthetized with 1.5-2.0 % isoflurane (Baxter Healthcare) at 2 ml/min in oxygen and PET/CT imaging was accomplished over 15 min. Images were analyzed using AsiPro VM™ software (Concorde Microsystems) and Inveon research workplace 4.1 software (Siemens Healthcare).
SPECT/CT Imaging SPECT/CT scans were performed using a small-animal NanoSPECT/CT from Mediso Medical Imaging Systems (Boston, MA). [ 9 9 m Tc]EC20 (501 ± 11 μCi, 18.5 ± 0.4 MBq, 3.1 nmol, 200 μl PBS containing 10 % ethanol) was administered into KB tumorbearing female athymic nude mice (n = 3) via tail vein 24 h after PET studies. At 2 and 4 h post injection, the mice were anesthetized with 1.5-2.0 % isoflurane (Baxter Healthcare) at 2 ml/min in oxygen and SPECT/CT data was collected over 30 min.
Biodistribution Experiments Female athymic nude mice (n = 3) bearing subcutaneous KB (right shoulder) xenografts were euthanized after imaging studies (4 h post injection) through asphyxiation with CO 2 . Organs of interested were harvested, weighed, and counted using a WIZARD 2 automatic γ-counter from PerkinElmer. The percentage of tracer uptake stated as percentage injected dose per gram of tissue (%ID/g) was calculated as the activity associated with tissue per organ weight per actual injected dose, decay-corrected to the start time of counting.
Statistical Analysis Statistical analysis was performed by
Prism software (version 6, GraphPad Software Inc.). The reported values are mean ± standard deviation. (Fig. 3a and Fig. S5) . Blocking experiments performed with an excess of folic acid showed less than 0.1 % nonspecific binding of both radiotracers, demonstrating their high specificity for the folate receptor in vitro. In addition, both radiotracers showed negligible uptake (0.28 ± 0.07 and 0. 20 (Fig. 3b) . In general, high relative stability (995 %) of both radioligands could be observed over the 240-min time period. We also compared the protein binding of both tracers 30 min after incubation ( Figure S4 ). [
Results
In Vitro Receptor Binding Studies
99m Tc]EC20 binds to serum proteins to an extent of~33 % after 30 min, whereas [
68 Ga]NOTA-folate binds to serum protein at a lower extent of~14 %.
PET/CT and SPECT Imaging Studies Already after 1 h post injection, the PET images with [
68 Ga]NOTA-folate showed high focal uptake in the tumor (5.66 ± 1.33 %ID/g) as well as activity in kidneys and bladder. There was also mild uptake in the GI tract. Neither for [
68 Ga]NOTA-folate nor [
99m Tc]EC20, uptake in the salivary glands was observed [6] . Images at 2 and 4 h post injection showed no major change in the biodistribution (see Fig. S2 ). Tumor uptake at these two time points was 5.62 ± 1.46 and 5.67 ± 1.69 %ID/g, respectively. To show specificity of [ 68 Ga]NOTA-folate (252 μCi, 9.3 MBq, 3.1 nmol) toward folate receptor in whole-body PET imaging, we further conducted blocking studies by co-injection of EC20 (12.5 nmol) . PET demonstrated effective blocking of KB tumor uptake by NOTA-folate (Figs. 4 and 5) .
The SPECT images with EC20 showed similar uptake of tumor, kidney, and bladder. In addition, tracer uptake was seen in the liver and gallbladder (Fig. S3) . Fig. 4 and Table S1 . The uptake (%ID/g) as well as the tumor-to-organ ratios of the imaging agents in selected organs of interest are summarized in Fig. 4 molecule drug conjugates (SMDCs) such as vintafolide [25, 26] . Surprisingly, uptake of the radiotracer in the saliva glands was not observed, in spite of their high folate expression [6] .
Biodistribution Studies
As we have previously pointed out, the [ 68 Ga]NOTAfolate PET imaging agent is by far not the first folatetargeted PET conjugate described in the literature. As a matter of fact, numerous of folate-conjugated PET agents have already been proven to visualize FR-positive tumors in vivo [3, [28] [29] [30] [31] [33] [34] [35] [36] [37] [38] . In the past, different approaches were utilized for the synthesis of folate-based PET radiotracers. To our knowledge, current preclinical PET imaging tracers are based on either F-18 [14, 28-30, 33, 38] or 31, [34] [35] [36] [37] as a radionuclide for in vivo imaging. All imaging tracers were able to successfully delineate folate receptor-positive tumors in animal models. These previous results encouraged us explore additional folate-targeted PET imaging tracers that could potentially meet the requirements for translation into the clinic. Ga-68 was picked out ahead of F-18 not only because of its easier radiolabeling chemistry, but also because of the flexibility provided by long-lived Ge-68/Ga-68 generators that allow the synthesis of the radiotracer without an on-site cyclotron [3] . Here, we compared our folate-derived Ga-68-based PET imaging agent to [ 99m Tc]EC20, a previously well-established imaging tracer, which was already used in several clinical trials for the delineation of folate receptor-positive solid tumors [39] .
Conclusion
In summary, we radiolabeled and biologically characterized a new Ga-68 folate-targeted PET imaging agent. Excellent PET images of folate receptor-positive tumors were obtained in mice. In a head-to-head comparison with the established SPECT folate receptor imaging agent, [
99m Tc]EC20, the new 68 Ga-based imaging agent showed encouraging tumor to organ ratios in vivo. Thus, [
68 Ga]NOTA-folate could be a suitable imaging probe to detect FR-positive tumors and to quantitatively assess their folate receptor expression levels.
